Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast: early-phase trial registry
2 of 4 indexed Human Epidermal Growth Factor 2 Negative Carcinoma of Breast trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 2 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast: 4 US clinical trials tracked, 2 recruiting.
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is Dana-Farber Cancer Institute, running 2 of these trials.
Enrollment posture brief
Registry condition human-epidermal-growth-factor-2-negative-carcinoma-of-breast
OPEN 2 | RECR 50% | LATE 0 | EARLY 4 | RANK #4115 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast lists 2 open slots (50% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Human Epidermal Growth Factor 2 Negative Carcinoma of Breast on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast is recruiting above its size-band peers.
2 of 4 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
Kristina A. Fanucci
NCT07222215
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
Incyclix Bio
NCT05735080
A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer
Dana-Farber Cancer Institute
NCT02623972
Palbociclib With Everolimus + Exemestane In BC
Dana-Farber Cancer Institute
NCT02871791
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Human Epidermal Growth Factor 2 Negative Carcinoma of Breast records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Human Epidermal Growth Factor 2 Negative Carcinoma of Breast trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Human Epidermal Growth Factor 2 Negative Carcinoma of Breast page
4 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Human Epidermal Growth Factor 2 Negative Carcinoma of Breast trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Dana-Farber Cancer Institute sponsors the most Human Epidermal Growth Factor 2 Negative Carcinoma of Breast trials on record, review their full trial history before evaluating a specific study. See Dana-Farber Cancer Institute's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Human Epidermal Growth Factor 2 Negative Carcinoma of Breast condition card totals 4 registered trials; most-linked intervention Adriamycin; top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.